Evidence map›Paper›PMID 34983506›Full record

ArticleMicrobial cell factories2022

Xanthoepocin, a photolabile antibiotic of Penicillium ochrochloron CBS 123823 with high activity against multiresistant gram-positive bacteria.

Pamela Vrabl, Bianka Siewert, Jacqueline Winkler, Harald Schöbel, Christoph W Schinagl, Ludwig Knabl, Dorothea Orth-Höller, Johannes Fiala, Michael S Meijer, Sylvestre Bonnet and 1 more

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Light regulation of secondary metabolism in fungi.Journal of biological engineering · 2023
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Pamela VrablInstitute of Microbiology, University of Innsbruck, Technikerstraße 25d, 6020, Innsbruck, Austria. Pamela.Vrabl@uibk.ac.at.ORCID http://orcid.org/0000-0002-8104-8684
Bianka SiewertInstitute of Pharmacy/Pharmacognosy, Center for Molecular Biosciences Innsbruck (CMBI), Center for Chemistry and Biomedicine, University of Innsbruck, Innrain 80-82, 6020, Innsbruck, Austria. Bianka.Siewert@uibk.ac.at.
Jacqueline WinklerInstitute of Microbiology, University of Innsbruck, Technikerstraße 25d, 6020, Innsbruck, Austria.
Harald SchöbelMCI - The Entrepreneurial University, Maximilianstraße 2, 6020, Innsbruck, Austria.
Christoph W SchinaglInstitute of Microbiology, University of Innsbruck, Technikerstraße 25d, 6020, Innsbruck, Austria.
Ludwig KnablDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstraße 41, 6020, Innsbruck, Austria.
Dorothea Orth-HöllerDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstraße 41, 6020, Innsbruck, Austria.
Johannes FialaInstitute of Microbiology, University of Innsbruck, Technikerstraße 25d, 6020, Innsbruck, Austria.
Michael S MeijerLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333CC, Leiden, The Netherlands.
Sylvestre BonnetLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333CC, Leiden, The Netherlands.
Wolfgang BurgstallerInstitute of Microbiology, University of Innsbruck, Technikerstraße 25d, 6020, Innsbruck, Austria.
Universität Innsbruck · ATInnsbruck Medical University · ATLeiden University · NLManagement Center Innsbruck · AT

Funding

Austrian Science Fund T862Austrian Science Fund FWF T 862
6 · The paper itself

Abstract

backgroundWith the steady increase of antibiotic resistance, several strategies have been proposed in the scientific community to overcome the crisis. One of many successful strategies is the re-evaluation of known compounds, which have been early discarded out of the pipeline, with state-of-the-art know-how. Xanthoepocin, a polyketide widespread among the genus Penicillium with an interesting bioactivity spectrum against gram-positive bacteria, is such a discarded antibiotic. The purpose of this work was to (i) isolate larger quantities of this metabolite and chemically re-evaluate it with modern technology, (ii) to explore which factors lead to xanthoepocin biosynthesis in P. ochrochloron, and (iii) to test if it is beside its known activity against methicillin-resistant Staphylococcus aureus (MRSA), also active against linezolid and vancomycin-resistant Enterococcus faecium (LVRE)-a very problematic resistant bacterium which is currently on the rise.

resultsIn this work, we developed several new protocols to isolate, extract, and quantify xanthoepocin out of bioreactor batch and petri dish-grown mycelium of P. ochrochloron. The (photo)chemical re-evaluation with state-of-the-art techniques revealed that xanthoepocin is a photolabile molecule, which produces singlet oxygen under blue light irradiation. The intracellular xanthoepocin content, which was highest under ammonium-limited conditions, varied considerably with the applied irradiation conditions in petri dish and bioreactor batch cultures. Using light-protecting measures, we achieved MIC values against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), which were up to 5 times lower than previously published. In addition, xanthoepocin was highly active against a clinical isolate of linezolid and vancomycin-resistant Enterococcus faecium (LVRE).

conclusionsThis interdisciplinary work underlines that the re-evaluation of known compounds with state-of-the-art techniques is an important strategy in the combat against multiresistant bacteria and that light is a crucial factor on many levels that needs to receive more attention. With appropriate light protecting measures in the susceptibility tests, xanthoepocin proved to be a powerful antibiotic against MRSA and LVRE. Exploring the light response of other polyketides may be pivotal for re-introducing previously discarded metabolites into the antibiotic pipeline and to identify photosensitizers which might be used for (antimicrobial) photodynamic therapies.

Indexed as

Drug Resistance, Multiple, BacterialLightAnti-Bacterial AgentsDynamic Light ScatteringEpoxy CompoundsGram-Positive BacteriaMicrobial Sensitivity TestsPenicilliumPhotolysisPyronesAnti-Bacterial AgentsEpoxy CompoundsPyronesXanthoepocinFilamentous fungiLightLight-dependent produced secondary metaboliteLVREMRSAPDTPhotoantimicrobial testReexamination of a known secondary metaboliteROS

Identifiers

PMID34983506
PMCPMC8725544
OpenAlexW4206557476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.